Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline
- PMID: 30351346
- PMCID: PMC6669409
- DOI: 10.1093/brain/awy264
Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline
Abstract
Alzheimer's disease is a heterogeneous disorder. Understanding the biological basis for this heterogeneity is key for developing personalized medicine. We identified atrophy subtypes in Alzheimer's disease dementia and tested whether these subtypes are already present in prodromal Alzheimer's disease and could explain interindividual differences in cognitive decline. First we retrospectively identified atrophy subtypes from structural MRI with a data-driven cluster analysis in three datasets of patients with Alzheimer's disease dementia: discovery data (dataset 1: n = 299, age = 67 ± 8, 50% female), and two independent external validation datasets (dataset 2: n = 181, age = 66 ± 7, 52% female; dataset 3: n = 227, age = 74 ± 8, 44% female). Subtypes were compared on clinical, cognitive and biological characteristics. Next, we classified prodromal Alzheimer's disease participants (n = 603, age = 72 ± 8, 43% female) according to the best matching subtype to their atrophy pattern, and we tested whether subtypes showed cognitive decline in specific domains. In all Alzheimer's disease dementia datasets we consistently identified four atrophy subtypes: (i) medial-temporal predominant atrophy with worst memory and language function, older age, lowest CSF tau levels and highest amount of vascular lesions; (ii) parieto-occipital atrophy with poor executive/attention and visuospatial functioning and high CSF tau; (iii) mild atrophy with best cognitive performance, young age, but highest CSF tau levels; and (iv) diffuse cortical atrophy with intermediate clinical, cognitive and biological features. Prodromal Alzheimer's disease participants classified into one of these subtypes showed similar subtype characteristics at baseline as Alzheimer's disease dementia subtypes. Compared across subtypes in prodromal Alzheimer's disease, the medial-temporal subtype showed fastest decline in memory and language over time; the parieto-occipital subtype declined fastest on executive/attention domain; the diffuse subtype in visuospatial functioning; and the mild subtype showed intermediate decline in all domains. Robust atrophy subtypes exist in Alzheimer's disease with distinct clinical and biological disease expression. Here we observe that these subtypes can already be detected in prodromal Alzheimer's disease, and that these may inform on expected trajectories of cognitive decline.
Figures





Comment in
-
Exploring Alzheimer's disease subtypes at the prodromal stage.Brain. 2018 Dec 1;141(12):3285-3287. doi: 10.1093/brain/awy282. Brain. 2018. PMID: 30496363 No abstract available.
Similar articles
-
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.Brain. 2024 Jul 5;147(7):2400-2413. doi: 10.1093/brain/awae118. Brain. 2024. PMID: 38654513 Free PMC article.
-
Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.Neuroimage Clin. 2019;22:101786. doi: 10.1016/j.nicl.2019.101786. Epub 2019 Mar 19. Neuroimage Clin. 2019. PMID: 30921610 Free PMC article.
-
Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.Brain. 2017 Mar 1;140(3):735-747. doi: 10.1093/brain/aww319. Brain. 2017. PMID: 28003242 Free PMC article.
-
Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage.J Alzheimers Dis. 2011;26 Suppl 3:159-99. doi: 10.3233/JAD-2011-0043. J Alzheimers Dis. 2011. PMID: 21971460 Review.
-
Molecular imaging of dementia.Psychogeriatrics. 2012 Jun;12(2):106-14. doi: 10.1111/j.1479-8301.2012.00409.x. Psychogeriatrics. 2012. PMID: 22712644 Review.
Cited by
-
The Ventricular System Enlarges Abnormally in the Seventies, Earlier in Men, and First in the Frontal Horn: A Study Based on More Than 3,000 Scans.Front Aging Neurosci. 2019 Nov 5;11:294. doi: 10.3389/fnagi.2019.00294. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31749695 Free PMC article.
-
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.Brain. 2024 Jul 5;147(7):2400-2413. doi: 10.1093/brain/awae118. Brain. 2024. PMID: 38654513 Free PMC article.
-
Analyzing large Alzheimer's disease cognitive datasets: Considerations and challenges.Alzheimers Dement (Amst). 2020 Dec 7;12(1):e12135. doi: 10.1002/dad2.12135. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 33313379 Free PMC article.
-
Multi-scale semi-supervised clustering of brain images: Deriving disease subtypes.Med Image Anal. 2022 Jan;75:102304. doi: 10.1016/j.media.2021.102304. Epub 2021 Nov 11. Med Image Anal. 2022. PMID: 34818611 Free PMC article.
-
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease.Alzheimers Dement. 2020 Feb;16(2):335-344. doi: 10.1016/j.jalz.2019.08.201. Epub 2020 Jan 4. Alzheimers Dement. 2020. PMID: 31672482 Free PMC article.
References
-
- Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 2015; 36: 297–309. - PubMed
-
- Dice L. Measures of the amount of ecologic association between species. Ecology 1945; 26: 297–302.
-
- Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. . Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614–29. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical